Scientists recalculate the optimum binding energy for heterogeneous catalysis

In a discovery that could lead to the development of novel catalysts that do not rely on expensive rare metals, scientists have shown that the optimal binding energy can deviate from traditional calculations, which are based on equilibrium thermodynamics, at high reaction rates. This means that reconsidering the design of catalysts using the new calculations may be necessary to achieve the best rates.

Read more

First report of cotton blue disease in the United States

Reported from six counties in coastal Alabama in 2017, cotton blue disease affected approximately 25% of the state's cotton crop and caused a 4% yield loss. The disease was reported again in 2018, affecting 3-100% of cotton fields in Alabama but causing only a 1% yield loss. Symptoms, which include slowed plant growth, loss of chlorophyll, and dwarfing of infected leaves, usually do not appear until last August after full bloom. To date, there are no recommended strategies for management of this disease.

Read more

Why modified carbon nanotubes can help the reproducibility problem

Scientists have conducted an in-depth study on how carbon nanotubes with oxygen-containing groups can be used to greatly enhance the performance of perovskite solar cells. The newly discovered self-recrystallization ability of perovskite could lead to improvement of low-cost and efficient perovskite solar cells.

Read more

A new discovery: How our memories stabilize while we sleep

Scientists have shown that delta waves emitted while we sleep are not generalized periods of silence during which the cortex rests, as has been described for decades in the scientific literature. Instead, they isolate assemblies of neurons that play an essential role in long-term memory formation.

Read more

Candidate Ebola vaccine still effective when highly diluted, macaque study finds

A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine — approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo — remains fully protective against disease in experimentally infected monkeys, according to scientists. The investigators completed the dosage study using cynomolgus macaques and an updated vaccine component to match the EBOV Makona strain that circulated in West Africa from 2014-16.

Read more